Novo A/s is an investment fund managing more than $1.85 trillion ran by Barbara Due. There are currently 38 companies in Mrs. Due’s portfolio. The largest investments include Vanguard Index Fds and Brookfield Corp, together worth $439 billion.
As of 13th August 2024, Novo A/s’s top holding is 1,038,550 shares of Vanguard Index Fds currently worth over $278 billion and making up 15.0% of the portfolio value.
In addition, the fund holds 3,880,230 shares of Brookfield Corp worth $161 billion.
The third-largest holding is Tempus Ai Inc worth $143 billion and the next is Asml Holding N V worth $136 billion, with 133,336 shares owned.
Currently, Novo A/s's portfolio is worth at least $1.85 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Novo A/s office and employees reside in Hellerup, Denmark. According to the last 13-F report filed with the SEC, Barbara Due serves as the General Counsel at Novo A/s.
In the most recent 13F filing, Novo A/s revealed that it had opened a new position in
Vanguard Index Fds and bought 1,038,550 shares worth $278 billion.
The investment fund also strengthened its position in Vaxcyte by buying
105,000 additional shares.
This makes their stake in Vaxcyte total 950,000 shares worth $71.7 billion.
Vaxcyte dropped approximately 0.1% in the past year.
On the other hand, there are companies that Novo A/s is getting rid of from its portfolio.
Novo A/s closed its position in Edgewise Therapeutics Inc on 20th August 2024.
It sold the previously owned 6,344,430 shares for $116 billion.
Barbara Due also disclosed a decreased stake in Asml Holding N V by 0.3%.
This leaves the value of the investment at $136 billion and 133,336 shares.
The two most similar investment funds to Novo A/s are Cinctive Capital Management L.P. and Moors & Cabot. They manage $1.86 trillion and $1.85 trillion respectively.
Novo A/s’s portfolio is diversified across 5 sectors.
Currently, their heaviest sector is Health Care — making up 25.2% of
the total portfolio value.
The fund focuses on investments in the United States as
39.5% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
11% of the total holdings value.
On the other hand, small-cap stocks make up only 5.3% of the portfolio.
The average market cap of the portfolio companies is close to $128 billion.
These positions were updated on August 20th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Vanguard Index Fds |
Opened
1,038,550
|
$277,822,510,000 | 14.98% |
| Brookfield Corp |
No change
3,880,230
|
$161,184,754,000 | 8.69% |
| Tempus Ai Inc |
Opened
4,074,419
|
$142,604,665,000 | 7.69% |
| Asml Holding N V |
26.95%
133,336
|
$136,366,727,000 | 7.35% |
| Salesforce Inc |
No change
480,160
|
$123,449,136,000 | 6.66% |
| Edgewise Therapeutics Inc |
Closed
6,344,430
|
$115,722,403,000 | |
| Edgewise Therapeutics Inc |
Opened
6,344,430
|
$114,263,184,000 | 6.16% |
| Corcept Therapeutics Inc |
No change
2,411,362
|
$78,345,151,000 | 4.22% |
| Vaxcyte, Inc. |
12.43%
950,000
|
$71,734,500,000 | 3.87% |
| Insmed Inc |
40.27%
800,000
|
$53,600,000,000 | 2.89% |
| Mirum Pharmaceuticals Inc |
No change
1,500,000
|
$51,285,000,000 | 2.76% |
| Crinetics Pharmaceuticals In |
8.98%
1,000,000
|
$44,790,000,000 | 2.41% |
| Cable One Inc |
No change
118,403
|
$41,914,662,000 | 2.26% |
| Biomarin Pharmaceutical Inc. |
8.89%
490,000
|
$40,341,700,000 | 2.17% |
| Merus N.V |
Opened
675,000
|
$39,939,750,000 | 2.15% |
| Apple Inc |
No change
182,960
|
$38,535,035,000 | 2.08% |
| Alibaba Group Hldg Ltd |
No change
500,827
|
$36,059,544,000 | 1.94% |
| Pharvaris N V |
47.68%
1,725,000
|
$32,430,000,000 | 1.75% |
| Celldex Therapeutics Inc. |
Opened
850,000
|
$31,458,500,000 | 1.70% |
| 4d Molecular Therapeutics In |
No change
1,400,000
|
$29,386,000,000 | 1.58% |
| Lanzatech Global Inc |
No change
15,814,845
|
$29,257,463,000 | 1.58% |
| Alnylam Pharmaceuticals Inc |
No change
118,383
|
$28,767,069,000 | 1.55% |
| Arrivent Biopharma Inc |
39.26%
1,500,000
|
$27,825,000,000 | 1.50% |
| Viridian Therapeutics Inc |
81.82%
2,000,000
|
$26,020,000,000 | 1.40% |
| Cargo Therapeutics Inc |
23.52%
1,544,000
|
$25,352,480,000 | 1.37% |
| Amicus Therapeutics Inc |
No change
2,500,000
|
$24,800,000,000 | 1.34% |
| Brookfield Asset Managmt Ltd |
No change
627,207
|
$23,865,226,000 | 1.29% |
| Rocket Pharmaceuticals Inc |
4.76%
1,100,000
|
$23,683,000,000 | 1.28% |
| Lexeo Therapeutics Inc |
11.46%
1,450,500
|
$23,266,020,000 | 1.25% |
| Blueprint Medicines Corp |
51.20%
175,000
|
$18,861,500,000 | 1.02% |
| Inspire Med Sys Inc |
Closed
65,524
|
$14,073,900,000 | |
| Kyverna Therapeutics Inc |
150.00%
1,750,000
|
$13,125,000,000 | 0.71% |
| Morphic Hldg Inc |
Opened
375,000
|
$12,776,250,000 | 0.69% |
| Verve Therapeutics Inc |
20.00%
2,400,000
|
$11,712,000,000 | 0.63% |
| Metagenomi Inc |
3.50%
1,800,000
|
$7,344,000,000 | 0.40% |
| Io Biotech Inc |
12.95%
4,429,449
|
$5,182,455,000 | 0.28% |
| Treace Med Concepts Inc |
Closed
360,000
|
$4,698,000,000 | |
| AbCellera Biologics Inc. |
No change
1,126,915
|
$3,335,668,000 | 0.18% |
| Marqeta Inc |
No change
441,558
|
$2,419,738,000 | 0.13% |
| Galecto Inc. |
No change
2,497,791
|
$1,183,953,000 | 0.06% |
| Spero Therapeutics Inc |
No change
468,902
|
$609,573,000 | 0.03% |
| No transactions found | |||
| Showing first 500 out of 41 holdings | |||